Reaktionsgleichung
[N+:1]([C:4]1[O:8][C:7]([CH:9]=[CH:10][C:11]2[N:20]=[C:19](NC3C=CC(O)=CC=3)[C:18]3[C:13](=[CH:14][CH:15]=[CH:16][CH:17]=3)[N:12]=2)=[CH:6][CH:5]=1)([O-:3])=[O:2].Cl.C(N)(=[O:38])C1C(=CC=CC=1)N.CC1NC(=O)C2C(=CC=CC=2)N=1.C(OC(OC(=O)C)C1OC([N+]([O-])=O)=CC=1)(=O)C.[N+](C1OC(C=O)=CC=1)([O-])=O>>[N+:1]([C:4]1[O:8][C:7]([CH:9]=[CH:10][C:11]2[NH:20][C:19](=[O:38])[C:18]3[C:13](=[CH:14][CH:15]=[CH:16][CH:17]=3)[N:12]=2)=[CH:6][CH:5]=1)([O-:3])=[O:2]Komponenten
6
Edukt 5
Produkt 1
Versuchsvorschrift
This example shows preparation of 2-[2-(5-nitro-2-furyl)vinyl]-4-(p-hydroxyanilino)quinazoline, (V). In this preparation, anthranilamide hydrochloride was converted to 2-methyl-4-(3H)quinazolinone (I) and 5-nitrofurfurylidene diacetate to 5-nitro-2-furancarboxaldehyde (II); (I) and (II) were then reacted to obtain 2-[2-(5-nitro-2-furyl)vinyl]-4-(3H) quinazolinone (III); (III) was then chlorinated to obtain 2-[2-(5-nitro-2-furyl)vinyl]-4-chloroquinazoline (IV) which was reacted with p-aminophenol to obtain the desired product, 2-[2-(5-nitro-2-furyl)vinyl]-4-(p-hydroxyanilino)quinazoline (V) and referred to in subsequent examples as the product of Example I. The procedure in this preparation is as follows:
Quellen und Nachweise
- ORD-Eintrag
- ord-7949f31e1b6b4dab8fe54c539cf82dd9
- Quelldatensatz
- uspto-grants-1976_08
- Patentnummer
- US03973021
Verknüpfte Notizen
Wird geladen…